INTRODUCTION: The development of a living, autologous vascular graft with the ability to grow holds great promise for advancing the field of pediatric cardiothoracic surgery. OBJECTIVE: To evaluate the growth potential of a tissue-engineered vascular graft (TEVG) in a juvenile animal model. METHODS: Polyglycolic acid nonwoven mesh tubes (3-cm length, 1.3-cm id; Concordia Fibers) coated with a 10% copolymer solution of 50:50 L-lactide and epsilon-caprolactone were statically seeded with 1 x 10 cells/cm autologous bone marrow derived mononuclear cells. Eight TEVGs (7 seeded, 1 unseeded control) were implanted as inferior vena cava (IVC) interposition grafts in juvenile lambs. Subjects underwent bimonthly magnetic resonance angiography (Siemens 1.5 T) with vascular image analysis (www.BioimageSuite.org). One of 7-seeded grafts was explanted after 1 month and all others were explanted 6 months after implantation. Neotissue was characterized using qualitative histologic and immunohistochemical staining and quantitative biochemical analysis. RESULTS: All grafts explanted at 6 months were patent and increased in volume as measured by difference in pixel summation in magnetic resonance angiography at 1 month and 6 months. The volume of seeded TEVGs at explant averaged 126.9% +/- 9.9% of their volume at 1 month. Magnetic resonance imaging demonstrated no evidence of aneurysmal dilation. TEVG resembled the native IVC histologically and had comparable collagen (157.9 +/- 26.4 microg/mg), elastin (186.9 +/- 16.7 microg/mg), and glycosaminoglycan (9.7 +/- 0.8 microg/mg) contents. Immunohistochemical staining and Western blot analysis showed that Ephrin-B4, a determinant of normal venous development, was acquired in the seeded grafts 6 months after implantation. CONCLUSIONS: TEVGs demonstrate evidence of growth and venous development when implanted in the IVC of a juvenile lamb model.
INTRODUCTION: The development of a living, autologous vascular graft with the ability to grow holds great promise for advancing the field of pediatric cardiothoracic surgery. OBJECTIVE: To evaluate the growth potential of a tissue-engineered vascular graft (TEVG) in a juvenile animal model. METHODS:Polyglycolic acid nonwoven mesh tubes (3-cm length, 1.3-cm id; Concordia Fibers) coated with a 10% copolymer solution of 50:50 L-lactide and epsilon-caprolactone were statically seeded with 1 x 10 cells/cm autologous bone marrow derived mononuclear cells. Eight TEVGs (7 seeded, 1 unseeded control) were implanted as inferior vena cava (IVC) interposition grafts in juvenile lambs. Subjects underwent bimonthly magnetic resonance angiography (Siemens 1.5 T) with vascular image analysis (www.BioimageSuite.org). One of 7-seeded grafts was explanted after 1 month and all others were explanted 6 months after implantation. Neotissue was characterized using qualitative histologic and immunohistochemical staining and quantitative biochemical analysis. RESULTS: All grafts explanted at 6 months were patent and increased in volume as measured by difference in pixel summation in magnetic resonance angiography at 1 month and 6 months. The volume of seeded TEVGs at explant averaged 126.9% +/- 9.9% of their volume at 1 month. Magnetic resonance imaging demonstrated no evidence of aneurysmal dilation. TEVG resembled the native IVC histologically and had comparable collagen (157.9 +/- 26.4 microg/mg), elastin (186.9 +/- 16.7 microg/mg), and glycosaminoglycan (9.7 +/- 0.8 microg/mg) contents. Immunohistochemical staining and Western blot analysis showed that Ephrin-B4, a determinant of normal venous development, was acquired in the seeded grafts 6 months after implantation. CONCLUSIONS: TEVGs demonstrate evidence of growth and venous development when implanted in the IVC of a juvenile lamb model.
Authors: Jason D Roh; Matthew P Brennan; Reynold I Lopez-Soler; Peter M Fong; Amit Goyal; Alan Dardik; Christopher K Breuer Journal: J Pediatr Surg Date: 2007-01 Impact factor: 2.545
Authors: Jason D Roh; Gregory N Nelson; Brooks V Udelsman; Matthew P Brennan; Britt Lockhart; Peter M Fong; Reynold I Lopez-Soler; W Mark Saltzman; Christopher K Breuer Journal: Tissue Eng Date: 2007-11
Authors: B D Bennett; F C Zeigler; Q Gu; B Fendly; A D Goddard; N Gillett; W Matthews Journal: Proc Natl Acad Sci U S A Date: 1995-03-14 Impact factor: 11.205
Authors: T Shinoka; D Shum-Tim; P X Ma; R E Tanel; N Isogai; R Langer; J P Vacanti; J E Mayer Journal: J Thorac Cardiovasc Surg Date: 1998-03 Impact factor: 5.209
Authors: N D Lawson; N Scheer; V N Pham; C H Kim; A B Chitnis; J A Campos-Ortega; B M Weinstein Journal: Development Date: 2001-10 Impact factor: 6.868
Authors: Yaohua Gao; Tai Yi; Toshiharu Shinoka; Yong Ung Lee; Darrell H Reneker; Christopher K Breuer; Matthew L Becker Journal: Adv Healthc Mater Date: 2016-07-08 Impact factor: 9.933
Authors: Joseph T Patterson; Thomas Gilliland; Mark W Maxfield; Spencer Church; Yuji Naito; Toshiharu Shinoka; Christopher K Breuer Journal: Regen Med Date: 2012-05 Impact factor: 3.806
Authors: Mitchel R Stacy; Yuji Naito; Mark W Maxfield; Hirotsugu Kurobe; Shuhei Tara; Chung Chan; Kevin A Rocco; Toshiharu Shinoka; Albert J Sinusas; Christopher K Breuer Journal: J Thorac Cardiovasc Surg Date: 2014-05-21 Impact factor: 5.209
Authors: Benedikt Weber; Maximilian Y Emmert; Roman Schoenauer; Chad Brokopp; Laura Baumgartner; Simon P Hoerstrup Journal: Semin Immunopathol Date: 2011-01-29 Impact factor: 9.623
Authors: Takuma Fukunishi; Cameron A Best; Chin Siang Ong; Tyler Groehl; James Reinhardt; Tai Yi; Hideki Miyachi; Huaitao Zhang; Toshiharu Shinoka; Christopher K Breuer; Jed Johnson; Narutoshi Hibino Journal: Tissue Eng Part A Date: 2017-06-13 Impact factor: 3.845
Authors: Mark W Maxfield; Mitchel R Stacy; Hirotsugu Kurobe; Shuhei Tara; Tai Yi; Muriel A Cleary; Zhen W Zhuang; Manuel I Rodriguez-Davalos; Sukru H Emre; Yasuko Iwakiri; Toshiharu Shinoka; Christopher K Breuer Journal: Regen Med Date: 2017-12-07 Impact factor: 3.806